3 results
To study the efficacy of the EmBlocker* in heart operations. The EmBlocker* is placed in the thorax cavity and will reroute by the use of ultrasound the emboli in the aorta curve to the aorta descendens, in order to reduce the amount of emboli in…
This study aims to test the hypothesis that zandelisib in combination with rituximab has better clinical activity and risk/benefit profile compared to standard 2nd line immunochemotherapy (R-CHOP/R-B) in subjects with relapsed FL or MZL. Primary…
Primary ObjectiveThe primary objective of this study is to evaluate whether the addition of ibrutinib to bendamustine and rituximab will result in prolongation of PFS in subjects with newly diagnosed MCL who are 65 years of age or older.Secondary…